ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of Fufangdanshen Tablets in Mild to Moderate Vascular Dementia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01761227
Recruitment Status : Unknown
Verified June 2015 by Jinzhou Tian, Dongzhimen Hospital, Beijing.
Recruitment status was:  Active, not recruiting
First Posted : January 4, 2013
Last Update Posted : June 3, 2015
Sponsor:
Collaborator:
Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited
Information provided by (Responsible Party):
Jinzhou Tian, Dongzhimen Hospital, Beijing

January 2, 2013
January 4, 2013
June 3, 2015
September 2012
December 2015   (Final data collection date for primary outcome measure)
  • Change from baseline to end of double-blind treatment Clinician's Interview Based Impression of Change - Plus Caregiver Input; Alzheimer Disease Assessment Scale-cognitive subscale [ Time Frame: 24 weeks ]
    Global cognition was assessed with the CIBIC-plus, at baseline (day 1 clinic visit) and at 12-week intervals thereafter until week 24.
  • Change in cognitive scores: Alzheimer Disease Assessment Scale-cognitive. subscale (ADAS-cog) [ Time Frame: 24 weeks ]
    Cognition was assessed with the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog), at baseline (day 1 clinic visit) and at 12-week intervals thereafter until week 24.
Same as current
Complete list of historical versions of study NCT01761227 on ClinicalTrials.gov Archive Site
  • Change in functional scores: Activities of Daily Living (ADL). [ Time Frame: 24 weeks ]
    Functional ability was evaluated with the ADL was evaluated at baseline (day 1 clinic visit), at the mid-study (week 12), and at the endpoint of treatment (week 24).
  • Change from baseline to the end of double-blind treatment in Mini-mental state examination (MMSE) scores [ Time Frame: 24 weeks ]
    Change in global cognition:Mini-mental state examination at baseline (day 1 clinic visit) and at 12-week intervals thereafter until week 24.
Same as current
Not Provided
Not Provided
 
Efficacy and Safety of Fufangdanshen Tablets in Mild to Moderate Vascular Dementia
The Safety and Efficacy of Fufangdanshen Tablets in Treatment of Mild to Moderate Vascular Dementia: a 24-week, Double Blind, Randomized, Parallel,Placebo Controlled Trial.
Purpose: The purpose of this study is to examine the efficacy and safety of Fufangdanshen Tablets in patients with mild to moderate vascular dementia (VaD).
This multicenter, double-blind, placebo-controlled study will evaluate the safety and effectiveness of Fufangdanshen Tablets in patients with vascular dementia. All patients will initially receive placebo for a 2 weeks period and then will receive Fufangdanshen Tablets or placebo for 6 months. The primary measures of effectiveness include the change from baseline to the end of treatment in the ADAS-cog/11 score (Alzheimer's Disease Assessment Scale: sum of 11 cognitive items) and the CIBIC-plus score (Clinician's Interview Based Impression of Change - Plus Caregiver Input). Additional measures of effectiveness include the change from baseline to the end of the treatment in the MMSE score (Mini-mental State Examination), the ADL (Ability of Daily Living) score. Safety evaluations (incidence of adverse events, electrocardiograms (ECGs), physical examinations, laboratory tests) will be performed throughout the study. Patients who complete the double-blind portion of the study will be followed up 12 weeks. Effectiveness will be assessed at 12 weeks, 24weeks and 36 weeks. Safety evaluations (incidence of adverse events, ECGs, physical examinations, laboratory tests) will be performed at 12 weeks, 24weeks and 36 weeks of the study. The study hypothesis is that Fufangdanshen Tablets will be effective in the treatment of patients with vascular dementia and will be well tolerated. Double-blind: Fufangdanshen Tablets: 3 tablets per time, 3 times per day, and placebo : 3 tablets per time, 3 times per day. The placebo has similar smile and appearance as the Fufangdanshen Tablets.
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Vascular Dementia
  • Drug: Fufangdanshen Tablets
    1 tablets contains contains tanshinoneⅡA 0.67mg , salvianolic acid B 8.2mg, Panax Notoginsenosides R1 0.53mg, ginsenoside Rb1 3.03mg, ginsenoside Rg1 2.73mg, 3 tablets per time, 3 times per day for 24 weeks
  • Drug: Placebo
    Placebo for 3 tablets per time, 3 times per day for 24 weeks
  • Experimental: Fufangdanshen Tablets
    1 tablets contains contains tanshinoneⅡA 0.67mg , salvianolic acid B 8.2mg, Panax Notoginsenosides R1 0.53mg, ginsenoside Rb1 3.03mg, ginsenoside Rg1 2.73mg, 3 tablets per time, 3 times per day for 24 weeks
    Intervention: Drug: Fufangdanshen Tablets
  • Placebo Comparator: Placebo
    3 tablets per time, 3 times per day for 24 weeks. The placebo has similar smile and appearance as the Fufangdanshen Tablets
    Intervention: Drug: Placebo
Tian J, Shi J, Wei M, Qin R, Ni J, Zhang X, Li T, Wang Y. The efficacy and safety of Fufangdanshen tablets (Radix Salviae miltiorrhizae formula tablets) for mild to moderate vascular dementia: a study protocol for a randomized controlled trial. Trials. 2016 Jun 8;17(1):281. doi: 10.1186/s13063-016-1410-5.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
240
Same as current
December 2015
December 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Inpatients and outpatients meeting the diagnostic criteria probable VaD established according to the Diagnostic and Statistical Manual of Mental Disorders (fourth edition) (DSM-Ⅳ) and the National Institute of Neurological Disorders and Stroke and the Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS-AIREN)were eligible to participate.
  • Weighing between 45 to 90 kg;
  • The diagnosis had also to be compatible with the findings from a recent (within last 12 months) magnetic resonance image (MRI) of the brain and
  • The Hachinski Ischemia Scale (HIS) score>4.
  • six months' mild to moderate VaD duration before inclusion.
  • Mild-to-moderate dementia (Score of the Mini-Mental State Examination (MMSE) defined as between 11 to 26)
  • The Hamilton Depression Scale (HAMD for 17 items) had a score of ≤ 12
  • have a consistent informant to accompany them on scheduled visits
  • Ability to read, write, communicate, and understand cognitive testing instructions

Exclusion Criteria:

  • Neurodegenerative disorders such as Parkinson's disease, with AD and any other secondary types of dementia;
  • cognitive impairment resulting from conditions such as acute cerebral trauma, cerebral damage due to a lack of oxygen, vitamin deficiency, infections such as meningitis or AIDS, significant endocrine or metabolic disease, mental retardation, or a brain tumor
  • having significant psychiatric disease, active peptic ulcer, clinically significant liver, kidney or lung disorders, or heart disease
  • history of epilepsy, convulsions, drug abuse or alcohol abuse
  • history of hypersensitivity to the treatment drugs;
  • concomitant drugs with the potential to interfere with cognition;
  • administration of other investigational drugs;
  • females of child bearing potential without adequate contraception
Sexes Eligible for Study: All
45 Years to 80 Years   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
China
 
 
NCT01761227
SFDA2005L01916
SFDA【2008】I919
Yes
Not Provided
Not Provided
Jinzhou Tian, Dongzhimen Hospital, Beijing
Dongzhimen Hospital, Beijing
Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited
Principal Investigator: Jinzhou Tian, Ph.D, M.D Dongzhimen Hospital,Beijing University of Chinese Medicine
Principal Investigator: Jing Shi, M.D Dongzhimen Hospital,Beijing University of Chinese Medicine
Dongzhimen Hospital, Beijing
June 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP